VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MRNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MRNAModerna, Inc.
$206.80$82.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMRNACash Flow

Moderna, Inc. (MRNA) Cash Flow Statement

10Y historyFree accessUpdated daily

Free cash flow was -$1.6B in Q3 2026 (-122.3% margin) against a cash balance that fell to $1.2B, suggesting limited runway and no shareholder returns, with dividends at $0 across the period.

Income StatementBalance SheetCash FlowRatios

MRNA Cash Flow Statement

Annual statement

MRNA Cash Flow Statement

Moderna, Inc. (MRNA) cash flow statement — 10-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Cash from Operations-1.76B-1.87B-3B-3.12B4.98B13.62B2.03B-458.97M-330.87M-331.48M66.73M
Operating CF Margin %--96.35%-93.9%-45.53%26.39%76.79%252.3%-762.29%-244.96%-161.05%61.57%
Operating CF Growth %13.22%37.65%3.66%-162.6%-63.43%571.94%541.64%-38.72%0.19%-596.72%-
Net Income-2.79B-2.82B-3.56B-4.71B8.36B12.2B-747.06M-514.02M-384.73M-255.92M-216.21M
Depreciation & Amortization257M215M189M621M348M232M31M31.02M24.86M20.54M15.11M
Stock-Based Compensation351M483M429M305M226M142M93M81.12M72.56M40.05M39.36M
Deferred Taxes000828M-559M-318M10.42M000288K
Other Non-Cash Items213M-3M17M-19M59M54M62.56M-3.43M-975K1.09M2.19M
Working Capital Changes204M254M-78M-139M-3.46B1.31B2.58B-53.66M-42.58M-137.25M225.99M
Change in Receivables-325M156M534M493M1.79B-1.78B-1.39B7.22M832K106K52.34M
Change in Inventory20M-34M83M747M492M-1.39B-46.53M7.2M4.41M34.8M-582K
Change in Payables-10M-92M-69M13M240M204M11.88M-23.96M15.02M-12.77M5.99M
Cash from Investing-1.51B1.95B1.95B4.21B-5.18B-8.52B-1.67B-14.95M-372.47M416.1M-648.61M
Capital Expenditures-185M-192M-1.05B-707M-400M-284M-67.45M-31.55M-105.77M-58.4M-33.14M
CapEx % of Revenue7.33%9.88%32.85%10.32%2.12%1.6%8.4%52.41%78.31%28.37%30.58%
Acquisitions000-85M0000000
Investments-----------
Other Investing-74M-10M00-40M-30M00622K-1.27M-8.9M
Cash from Financing3.34B593M56M-1.38B-3.45B-873M2.03B51.12M1.23B168K472.91M
Debt Issued (Net)3.54B539M-10M-270M-184M-140M-6M1M9.46M1.44M0
Equity Issued (Net)186M35M66M-1.11B-3.26B-733M2.04B50.15M1.22B212K473.53M
Dividends Paid000000000-1.48M-633K
Share Repurchases-2M00-1.15B-3.33B-857M02.89M-8.18M00
Other Financing-385M19M0000193K-29K0011K
Net Change in Cash61M668M-999M-289M-3.64B4.22B2.39B-422.79M523.5M84.78M-108.96M
Free Cash Flow-1.95B-2.06B-4.05B-3.83B4.58B13.34B1.96B-490.52M-436.63M-389.88M33.59M
FCF Margin %-77.19%-106.22%-126.76%-55.86%24.27%75.19%243.91%-814.7%-323.27%-189.43%30.99%
FCF Growth %26.81%49.08%-6.01%-183.5%-65.65%580.57%499.48%-12.34%-11.99%-1260.72%-
FCF per Share-4.53-5.31-10.56-10.0111.0130.945.14-1.48-1.33-1.040.52
FCF Conversion (FCF/Net Income)0.70x0.66x0.84x0.66x0.60x1.12x-2.71x0.89x0.86x1.30x-0.31x
Interest Paid0024M39M25M14M9M03M00
Taxes Paid00197M02.73B480M1M0294K398K905K

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash burn outpacing commercial recovery

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Diverges From Operating Cash Flow

Based on reported quarterly figures, Moderna's operating cash flow was negative in six of the last ten quarters, while net income swung between profit and loss, leaving cash conversion weak and unreliable as an earnings signal.

The gap between net income and operating cash flow is the central issue, as the OCF-to-net-income ratio fluctuates erratically between negative and positive values that do not meaningfully track earnings. The Q3 2026 net income of $162.0M alongside operating cash flow of roughly -$1.6B suggests the reported profit is not translating into cash, and working capital movements of about -$1.9B appear to account for much of that divergence. Investors should treat the quarter's EPS beat with caution until cash generation confirms the earnings quality.

Free Cash Flow Remains Deeply Negative

As reported in the quarterly cash flow statements, Moderna's free cash flow margin was -122.3% in Q3 2026 and has been negative across most recent periods, with only isolated quarters showing positive free cash flow.

Free cash flow has oscillated between large negative readings and occasional positive quarters, most notably the $912M in Q4 2025 and $303M in Q4 2024, which appear tied to working capital timing rather than a sustained operating improvement. The persistent negative trend indicates the business has not yet reached a self-funding level despite the commercial launches. Sustained positive free cash flow would be needed to validate the recovery narrative.

Capex Spikes Reflect Capacity Uncertainty

According to the reported figures, capital expenditure has been modest in most quarters at roughly 2% to 8% of revenue, though it reached 109.3% and 82.4% of revenue in early 2025 and 2024, respectively.

The elevated capex readings in Q1 2025 and Q2 2024 appear to reflect manufacturing investment during periods of revenue weakness, which would be consistent with building capacity ahead of demand. The low capex levels in most recent quarters suggest the company has curtailed infrastructure spending, which may reflect capacity right-sizing. Depreciation of roughly $50M to $70M per quarter remains well below these historical spikes, leaving the asset base relatively unrefreshed.

No Shareholder Returns During Cash Burn

Based on reported cash flow data, Moderna paid no dividends across the ten quarters shown and recorded only minimal buybacks, with acquisition spending not disclosed.

The absence of dividends and near-zero repurchases is appropriate given sustained operating cash outflows, and capital is effectively being preserved to fund the research pipeline. Acquisition spending is not disclosed in the supplied data, so no conclusion can be drawn about inorganic deployment. Investors should monitor whether the company's cash position supports pipeline funding through the period of negative operating cash flow.

Q3 Inflection May Prove Isolated

Based on reported figures, Moderna's trailing net margin of -145.2% and cumulative quarterly losses exceeding $800M in several periods suggest the Q3 2026 profit may be an isolated event rather than the start of sustained profitability.

The Q3 2026 net income of $162.0M contrasts sharply with the operating cash outflow of roughly -$1.6B in the same quarter, indicating that the earnings improvement has not been accompanied by cash generation and may depend on accrual or timing effects. Several recent quarters, including Q2 2024 and Q1 2026, recorded substantial losses, which reinforces the view that one profitable quarter does not establish a durable trend. Investors should treat the inflection thesis as unconfirmed until positive operating cash flow persists across multiple consecutive periods.

MRNA — Frequently Asked Questions

Quick answers to the most common questions about buying MRNA stock.

How much cash does Moderna, Inc. (MRNA) generate from operations?

Moderna, Inc. (MRNA) generated $-1873.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Moderna, Inc.'s free cash flow?

Moderna, Inc. (MRNA) reported negative free cash flow of $2.06B in 2025, indicating capital requirements exceeded cash from operations.

What is Moderna, Inc.'s capital expenditure (CapEx)?

Moderna, Inc. (MRNA) spent $192.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.